Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as LUCAR-G79D T cells
LUCAR-G79D · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Chimeric antigen receptor T cells (LUCAR-G79D) | EXPERIMENTAL | Each subject will be given a single-dose LUCAR-G79D cells infusion at each dose level. |
| Name | Type | Description |
|---|---|---|
| LUCAR-G79D T cells | BIOLOGICAL | Prior to infusion of the LUCAR-G79D T cells, subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine. |
Inclusion Criteria: 1. Subjects voluntary agreement to provide written informed consent. 2. Aged 18 to 70 years, either sex. 3. Adequate organ function meet screening criteria. 4. Positive test for cluster of differentiation antigen 19 (CD19). SLE: * Have been diagnosed of SLE at least 6 months b...
Top 20 of 34 competitors
LUCAR-G79D is an investigational cell therapy being developed by Legend Biotech Corporation for relapsed or refractory systemic lupus erythematosus (SLE) and idiopathic inflammatory myopathies (IIM). It is also known as LUCAR-G79D T cells. It is currently in Phase 1 clinical development and has not been approved for any indication.
LUCAR-G79D is being studied for the treatment of relapsed or refractory systemic lupus erythematosus (SLE) and idiopathic inflammatory myopathies (IIM). These are autoimmune conditions, and the trial enrolls patients whose disease has not responded to prior therapy. The drug remains investigational and is not approved for any use.
LUCAR-G79D is being developed by Legend Biotech Corporation, which trades under the ticker LEGN. Legend Biotech is the sponsor of the Phase 1 study evaluating the therapy in autoimmune indications.
LUCAR-G79D is in Phase 1 clinical development. It is an investigational therapy and has not received FDA approval. The single ongoing study is currently recruiting participants, and no trials of LUCAR-G79D have been completed.
LUCAR-G79D is being evaluated in one Phase 1 trial, NCT07331272, titled A Study of LUCAR-G79D in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE) and Idiopathic Inflammatory Myopathies (r/r IIM). The study is recruiting, is uncontrolled, and plans to enroll 38 participants in China.
Yes, LUCAR-G79D T cells is another name for LUCAR-G79D. Both names refer to the same investigational therapy developed by Legend Biotech Corporation for relapsed or refractory systemic lupus erythematosus and idiopathic inflammatory myopathies.